Characterization of Gut Microbiota in Chronic Liver Disease With Decreased Muscle Mass

Completed

• Conditions: Liver Disease Chronic; Gastrointestinal Microbiome; Sarcopenia
• Interventions: Diagnostic Test: Sarcopenia_CT

• Registration Number: NCT05729269
• Lead Sponsor: Chuncheon Sacred Heart Hospital

Brief Summary

The purpose of this study was to confirm the presence of specific gut microbiota observed in patients with sarcopenia among patients who agreed to analyze gut microbiota through stool among multi-center chronic liver disease cohort patients.

Detailed Description

The effect of gut microbiota on liver disease is also well known and many studies are ongoing. A recently published study summarized the differences in the composition of gut microbiota in non-alcoholic fatty liver, steatohepatitis, and cirrhosis, and reported that metabolites from the changed gut microbiota may be a factor influencing non-alcoholic fatty liver disease (NAFLD) progression. These changes in gut microbiota composition have been reported to affect clinical outcomes in patients by causing an increase in endotoxin, a change in bile acid metabolism, and a decrease in short chain fatty acid. In particular, the reduction of short chain fatty acid is known to be associated with the occurrence of sarcopenia. Sarcopenia, which is common in patients with cirrhosis, which is a representative chronic liver disease, is well known as a poor prognostic factor for patients. Therefore, this study aims to analyze the distribution of gut microbiota observed in patients with sarcopenia through the gut microbiota investigated in the chronic liver disease cohort patient group and the characteristics of the distribution of gut microbiota for each disease corresponding to chronic liver disease.

Study Timeline

• Study Start: 2017-03-22
• Primary Completion: 2019-04-30
• Status Verified: 2021-04
• Study Completion: 2021-12-31
• Study First Submitted: 2023-02-06
• Study First Submitted QC: 2023-02-06
• Last Update Submitted: 2023-02-06
• Study First Posted: 2023-02-15
• Last Update Posted: 2023-02-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 283

Inclusion Criteria

• 1. Patients who have chronic liver disease (chronic liver disease cohort): alcohol liver disease, non-alcoholic liver disease, liver cirrhosis 2. Patients who consented to a study confirming the gut microbiota 3. Patients with abdominal computed tomography scan taken one month before or after submitting stool for gut microbiota analysis

Exclusion Criteria

• Patients whose height and weight records are missing from the chart review

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Chronic liver disease	Sarcopenia_CT	non-alcohol liver disease, alcohol liver disease, liver cirrhosis

Primary Outcome Measures

Name	Time	Method
Fecal gut microbiota between sarcopenia group and non-sarcopenia group	2 years	Compare the species and proportions of the gut microbiota between sarcopenia group and non-sarcopenia group

Trial Locations

Locations (1)

Department of Internal Medicine, Hallym University Medical College; 🇰🇷 Chuncheon, Gangwon-do, Korea, Republic of